GenScript Biotech Corporation, a leading company in life sciences innovation, has shared its financial results for the first half of 2025. These results show how the company is growing effectively while expanding its presence in different parts of the world. The success comes from its global strategy, strong technology, and ongoing innovation.
Health Technology Insights: Sectra Security Attestation Boosts Cloud Adoption in Germany
In the first six months of 2025, GenScript made about 518.8 million US dollars in total revenue, which is a big increase of 81.9 percent compared to the same period last year. The company’s gross profit went up by 140.1 percent to reach 320.6 million US dollars. Its adjusted net profit from ongoing operations jumped over five times, hitting 178 million US dollars. These numbers show that the company is running efficiently, with better profit margins and high demand across all areas of its business. The main reasons for this success include more contributions from international markets and better use of the company’s production capacity. GenScript also keeps up strong progress in sustainability, scoring well on environmental, social, and governance standards, which helps build long-term value for its stakeholders.
Sherry Shao, Rotating CEO of GenScript Biotech, commented on the results, saying, “Our first-half results strongly show the effectiveness of GenScript’s global strategy that is based on innovation and commercial success. We are committed to investing more in research and development, expanding production globally, and increasing our market presence to ensure sustainable growth and deliver better value to our customers and shareholders.”
Health Technology Insights: Daewoong Patch Shows Best-in-Class Bioavailability Results
The Life Science Services and Products segment earned 247.6 million US dollars in revenue, an 11.3 percent increase from the previous year. This growth was mainly due to higher volumes of gene synthesis and greater demand for protein products. Investments in automation and a broader range of products have helped the company keep up with demand while improving profitability. GenScript’s ability to scale its services while offering advanced tools for drug discovery and research has positioned it as a top provider in the global life science tools market.
GenScript’s biologics CDMO business, managed by ProBio, generated 246.9 million US dollars in revenue—an increase of 511.1 percent from H1 2024. The adjusted gross margin for this segment reached 73.6 percent thanks to better use of production capacity and more efficient operations. Even without a one-time payment from its collaboration with LaNova, ProBio still grew strongly. The unit has now licensed out sixteen assets, including four that are already in clinical development. Upcoming milestones, such as the possible out-licensing of its CD3 VHH asset by late 2025 or early 2026, support a positive outlook for the future and point toward long-term revenue opportunities.
GenScript’s industrial synthetic biology division, Bestzyme, also showed steady growth, with revenue up 8.4 percent. This growth came from better market reach for its innovative enzymes and stronger relationships with existing customers. Bestzyme now has 61 granted patents and has filed another 61 patent applications. One of its major developments, a sweet protein product, recently received FDA GRAS status. A dedicated manufacturing plant is expected to be ready by mid-2026, further supporting its expansion plans in industrial biotech and specialty ingredients.
GenScript’s global infrastructure remains a key strength. With research and production centers in the United States, Europe, and Asia, the company has achieved over 60 percent automation in its supply chain. This helps the company respond more quickly to market needs and improves its ability to handle challenges. A new brand refresh launched on August 8, combined with a strong Net Promoter Score, has helped improve customer satisfaction and drive the use of high-margin integrated products. In sustainability, GenScript leads the industry, earning top ESG scores including an MSCI AA rating, an EcoVadis Silver Medal, and a “Low Risk” rating from Sustainalytics. It has also improved its S&P Global score to 60 and remains listed on the FTSE4Good Index. Its science-based carbon reduction targets have been validated by the SBTi and are backed by global commitments like the UN Global Compact and the Pharmaceutical Supply Chain Initiative.
Looking forward, GenScript expects its growth to continue through more automation, expanded market reach, and a strong lineup of new and innovative solutions. Its focus on technology, global scale, and sustainability positions it well to maintain its leadership in the biotechnology sector and provide long-term value to its shareholders. With continued investment in R&D and capacity expansion, the company is poised to stay ahead in the evolving global biotech industry.
Health Technology Insights: HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
